Connect to other sites within the UBM Medica Network
Exposure to In Utero Chemotherapy Did Not Affect Children’s Development, Behavior
In this video we discuss two poster presentations on childhood development and behavior after in utero exposure to chemotherapy for maternal cancer in pregnancy.
Breast Cancer Not Overdiagnosed by Mammography
The idea that breast cancer is overdiagnosed is being perpetuated in an effort to reduce access to breast cancer screening, according to a presentation at MBCC.
Lung-RADS Reduces False Positives, Sensitivity of Lung Screening
A classification system known as Lung-RADS reduced false positive rates but also decreased the sensitivity of low-dose CT screening compared with NLST standards.
Maintenance Sunitinib Improved PFS in Extensive-Stage SCLC
In a phase II study, the use of maintenance sunitinib improved progression-free survival among patients with untreated extensive-stage small-cell lung cancer.
Sentinel Lymph Node Biopsy Indicated in Thick Melanomas
A single-institution study found that patients with melanomas of 4 mm thickness who had a negative sentinel lymph node biopsy had significantly prolonged survival.
Neutrophil-to-Lymphocyte Ratio Linked to mRCC Outcomes
Metastatic renal cell carcinoma patients with an elevated neutrophil-to-lymphocyte ratio at baseline had inferior outcomes compared those with a low ratio.
Decision-Making in the Management of Early Prostate Cancer
As part of our coverage of the ASCO GU Cancers Symposium, we discuss decision-making in the management of patients with early-stage prostate cancer.
FDA Approves Panobinostat for Multiple Myeloma
The FDA has approved panobinostat (Farydak), in combination with bortezomib and dexamethasone, for treating patients with multiple myeloma.
Adjuvant Chemotherapy Improves Survival in Bladder Cancer
Patients with bladder cancer derived an overall survival benefit from the use of adjuvant chemotherapy compared with observation.
Two Clinical Factors May Predict PSA Response to Cabazitaxel
Two clinical factors may predict PSA response to cabazitaxel in men with metastatic castration-resistant prostate cancer.
By clicking Accept, you agree to become a member of the UBM Medica Community.